4 Stocks Dragging The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 22 points (-0.1%) at 16,065 as of Monday, Dec. 2, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,030 issues advancing vs. 1,883 declining with 116 unchanged.

The Drugs industry currently sits down 0.4% versus the S&P 500, which is unchanged.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Shire ( SHPG) is one of the companies pushing the Drugs industry lower today. As of noon trading, Shire is down $2.81 (-2.1%) to $133.00 on light volume. Thus far, 162,198 shares of Shire exchanged hands as compared to its average daily volume of 454,700 shares. The stock has ranged in price between $132.65-$133.56 after having opened the day at $133.10 as compared to the previous trading day's close of $135.81.

Shire plc, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). Shire has a market cap of $25.5 billion and is part of the health care sector. The company has a P/E ratio of 36.9, above the S&P 500 P/E ratio of 17.7. Shares are up 47.5% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Shire a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Shire Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

Shire Gains as it Seeks European Approval For Dry Eye Treatment

Tesla and Apple Better Deliver Big-Time or Look Out Below -- Week Ahead